

Aflastende fodkirurgi versus Standard sårbehandling for Voksne med diabetiske fodsår

Review information

Authors

Sundhedsstyrelsen¹¹[Empty affiliation]

Citation example: S. Aflastende fodkirurgi versus Standard sårbehandling for Voksne med diabetiske fodsår. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Characteristics of studies

Characteristics of included studies

Allam 2006

| | |
|-----------------------|--|
| Methods | Study design: Randomized controlled trial Study grouping: Parallel group |
| Participants | Baseline Characteristics Overall <ul style="list-style-type: none"> ● <i>Age, mean (SD):</i> 55 (11) ● <i>BMI, mean (SD):</i> 35 (3) ● <i>mean duration of diabetes (years) SD:</i> 20 (11) ● <i>mean duration of the foot ulcer (months) range:</i> 42 (10-72) Included criteria: diabetic patients with plantar forefoot ulceration Excluded criteria: no exclusion criteria |
| Interventions | Intervention Characteristics Intervention <ul style="list-style-type: none"> ● <i>Description:</i> patients were treated by local ulcer care and Achilles tendon lengthening (ATL). The ankle was kept in slight dorsiflexion with a posterior plaster splint. The patients remained non-weight bearing for one week and the leg was placed in a walker with heel lift for further 5 weeks then the patients were allowed to weight bear after the 6th postoperative week. The sole ulcer was dressed daily and local care of the ulcer continued till complete healing. ● <i>duration:</i> active treatment for 6 weeks, until healing ● <i>followup:</i> 2 years Kontrol <ul style="list-style-type: none"> ● <i>Description:</i> patients were managed by local wound care and total contact cast alone (TCC). Below knee cast was applied with a window for daily dressing of the ulcer. Both groups the ulcer was debrided and dressed while systemic antibiotic was given according to culture sensitivity results: ● <i>duration:</i> until healing ● <i>followup:</i> 2 years |
| Outcomes | <i>Recidiv af sår, længste follow-up (op til 1 år)</i> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Endpoint <i>Sårheling, længste follow-up (op til 1 år)</i> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Unit of measure: n/N ● Direction: Higher is better ● Data value: Endpoint <i>Bivirkninger (DVT, lungeemboli, komplikationer i relation til operationssår), længste follow-up (op til 1 år)</i> <ul style="list-style-type: none"> ● Outcome type: Adverse Event ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Endpoint <i>Transfersår, Længste follow-up (op til 1 år)</i> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Endpoint |
| Identification | Sponsorship source: no funding Country: egypt Setting: Twenty nine diabetic patients with plantar forefoot ulceration were randomized into two groups: TCC og ATL at a university hospital Authors name: abdel mohsen allam Institution: The Department of General Surgery, Plastic & Reconstructive Surgery Unit, Tanta University. Email: no email Address: The Department of General Surgery, Plastic & Reconstructive Surgery Unit, Tanta University. El-Gharbia Governorate, Tanta . El-Gash st. Medical Campus The Faculty of Medicine |
| Notes | |

Risk of bias table

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence generation (selection bias) | Unclear risk | Quote: "forefoot ulceration. MATERIAL AND METHODS Twenty nine diabetic patients with plantar forefoot ulceration were randomized into two groups: • Group I (GI): 14 patients were managed by local wound care and total contact cast alone (TCC). • Group II (GII): 15 patients were treated by local ulcer care and Achilles tendon lengthening (ATL). Postoperatively, the patients were followed" Quote: "There were no significant differences in age, sex, or the duration of the plantar forefoot ulcerations between the studied groups." Judgement Comment: No information about randomisation method. |
| Allocation concealment (selection bias) | High risk | Judgement Comment: Not described. Likely no efforts made to conceal allocation. |
| Blinding of participants and personnel (performance bias) | High risk | Judgement Comment: No blinding of participants. No information about blinding of the personnel. |
| Blinding of outcome assessment (detection bias) | High risk | Judgement Comment: No description of blinding of outcome assessors. Likely no efforts made to blind. |
| Incomplete outcome data (attrition bias) | Low risk | Quote: "29 diabetic patients with plantar forefoot ulceration were allocated in two groups" Judgement Comment: No information about drop outs. Alle participants informed outcomes of interest for all time points. |
| Selective reporting (reporting bias) | Unclear risk | Judgement Comment: Only early complications reported for ATL group. No protocol |
| Other bias | Unclear risk | Judgement Comment: Only one author. No information about funding etc... |

Mueller 2003

| | |
|----------------------|--|
| Methods | Study design: Randomized controlled trial Study grouping: Parallel group |
| Participants | <p>Baseline Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Female, N (%): 5 (16.13) ● Age, mean (SD): 56.6 (9.2) ● BMI, mean (SD): 33.3 (7.8) ● Type 2 diabetes, N (%): 26 (83.87) ● Duration of diabetes (years): 17.1 (10.8) ● HbA1c, %: 8.8 (1.9) ● Peripheral neuropathy, N (%): 31 (100) <p>Kontrol 1</p> <ul style="list-style-type: none"> ● Female, N (%): 10 (3.03) ● Age, mean (SD): 56.2 (10.1) ● BMI, mean (SD): 30.5 (6.8) ● Type 2 diabetes, N (%): 22 (66.67) ● Duration of diabetes (years): 19.6 (12.6) ● HbA1c, %: 8.8 (1.7) ● Peripheral neuropathy, N (%): 33 (100) <p>Included criteria: Patients were considered for inclusion in the study if they had a history of diabetes mellitus, loss of protective sensation (unable to sense the 5.07 Semmes-Weinstein monofilament on at least one location on the plantar aspect of the foot), limitation of ankle dorsiflexion to $\leq 5^\circ$, a palpable ankle pulse, and a recurrent or nonhealing ulcer on the forefoot (Grade II according to the Wagner scale²¹). A limitation of 5° of ankle dorsiflexion was chosen because most authors believe that $\geq 10^\circ$ is required for normal walking ability²². A recurrent or nonhealing ulcer was defined as two or more occurrences of a plantar ulcer or the failure of a plantar ulcer to heal with conservative treatment (i.e., dressing changes and footwear modifications).</p> <p>Excluded criteria: Patients were excluded from the study if they had a neurological problem complicating the rehabilitation, had a history of Charcot fractures of the hindfoot, were unable to tolerate the anesthesia required for Achilles tendon lengthening, or if it was thought that they would not benefit from an Achilles tendon lengthening (i.e., they were not able to walk). We did not exclude individuals with a Charcot deformity of the midfoot or forefoot or a partial foot amputation if they met the above inclusion criteria.</p> |
| Interventions | <p>Intervention Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Description: All necrotic tissue and callus surrounding the ulcer were sharply debrided. The ulcer was covered with a dry gauze dressing. The subjects who were randomized to the Achilles tendon lengthening group were placed supine on the operating table, and intra-venous sedation was administered. After sterile preparation, local anesthesia was injected along the subcutaneous border of the Achilles tendon as a field block. Three hemisections were made in the Achilles tendon with use of the Hoke triple hemisection technique²⁶. Then the surgeon firmly pushed on the plantar aspect of the forefoot, dorsiflexing the ankle in a controlled manner to allow the Achilles tendon to lengthen along the course of its weakened fibers until the foot could be brought into 10° of dorsiflexion. Excessive force that might cause complete transection or overlengthening of the tendon was carefully avoided. No sutures were used to close the three tenotomy sites, and a dry gauze dressing (4 by 4 in [10 by 10 cm]) was applied and held in place with a sterile cotton wrap. After the Achilles tendon lengthening, a total-contact cast was applied as described previously²⁷, except that the distal end of the toe box was left open and a standard rocker cast shoe was used rather than a walking heel. The cast was applied to the leg with the ankle joint in a neutral position. The cast was initially changed after one week and was subsequently changed every two to three weeks for at least six weeks or until the forefoot ulcer had completely healed. The patient was allowed partial weight-bearing immediately after application of the total-contact cast and progressed to full weight-bearing after the first week but was asked to limit his or her activities as much as possible. After application of the cast, the involved foot was placed in a padded diabetic pressure-relief walking boot (DH Pressure Relief Walker; Royce Medical, Camarillo, California) for one to four weeks until the subject felt stable enough to walk with the extra-depth shoes with custom-molded inserts that ● Duration: 7 months ● Dose: one time surgery, +tcc changed every 2-3. week <p>Kontrol 1</p> <ul style="list-style-type: none"> ● Description: Subjects who were randomly assigned to the total-contact cast group were treated with a total-contact cast with use of methods identical to those used in the Achilles tendon lengthening group except that the patients were allowed full weight-bearing immediately after the initial application of the cast. The ankle was positioned as close to neutral as possible, and the cast was changed every two to three weeks until the plantar ulcer was healed. Subjects then were instructed to wear the extra-depth shoes with custom-molded inserts²⁸. After treatment, all subjects were instructed in a home-exercise program by a physical therapist with use of a Thera-Band (Hygenic, Akron, Ohio) to provide resistance to the musculature around the ankle. The |

| | |
|-----------------------|---|
| | <p>exercise program included use of a red Thera-Band, progressing to a green one to resist ankle plantar flexion, dorsiflexion, inversion, and eversion movements. Exercises were completed in three sets with ten repetitions in each set, one time per day, for three, four, or five days per week</p> <ul style="list-style-type: none"> ● Duration: 7 months ● Dose: tcc changed every 2-3. week |
| Outcomes | <p><i>Helbredsrelateret livskvalitet, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Reporting: Fully reported ● Scale: SF 36, General Health ● Range: 0-100 ● Unit of measure: Point ● Direction: Higher is better ● Data value: Endpoint <p><i>Selvrapporteret funktion, efter endt behandling</i></p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Reporting: Fully reported ● Scale: SF-36 Physical functioning ● Range: 0-100 ● Unit of measure: Point ● Direction: Higher is better ● Data value: Endpoint |
| Identification | <p>Sponsorship source: funding from the National Center for Medical Rehabilitation Research and the National Institutes of Health RO1 HD 36802.</p> <p>Country: USA</p> <p>Setting: Sixty-four subjects were randomized into two treatment groups, immobilization in a total-contact cast alone or combined with percutaneous Achilles tendon lengthening, with measurements made before and after treatment, at these seven-month follow-up examination, and at the final follow-up evaluation (a mean [and standard deviation] of 2.1 ± 0.7 years after initial healing).</p> <p>Authors name: Michael J Mueller</p> <p>Institution: Washington University School of Medicine, St. Louis, Missouri</p> <p>Email: muellermi@msnotes.wustl.edu</p> <p>Address: Program in Physical Therapy, Box 8502, 4444 Forest Park Boulevard, St. Louis, MO 63018.</p> |
| Notes | |

Risk of bias table

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence generation (selection bias) | Low risk | Quote: "were randomized into the Achilles tendon lengthening group or the total-contact cast group with use of a prearranged schedule generated by a computer program." Quote: "Randomization methods were successful as there were no differences between the groups with respect to any subject characteristic (p > 0.05)." Quote: "There were no differences between groups (p > 0.05) for any of these characteristics." Judgement Comment: No baseline differences |
| Allocation concealment (selection bias) | Unclear risk | Quote: "were unlikely to meet. The orthopaedic surgeon (J.E.J.), who screened all patients for eligibility into the study, was blind to the prearranged schedule. Once the subject agreed to participate, he or she was referred to the patient coordinator for the study who assigned the subject to a treatment group according to the prearranged schedule and arranged all testing sessions. Subject Characteristics Sixty-four subjects met" Judgement Comment: Unclear how the patient coordinator concealed the allocation for patients and personnel until after testing sessions. |
| Blinding of participants and personnel (performance bias) | High risk | Quote: "Because we anticipated a much higher rate of reulceration in the total-contact cast group compared with that in the Achilles tendon lengthening group, and we wanted subjects to have the opportunity to cross over to the Achilles tendon lengthening group if treatment with a total-contact cast alone was not successful, the prearranged schedule was planned to enroll two times as many subjects in the total-contact cast group as in the Achilles tendon lengthening group. Subjects who had a reulceration after treatment with a total-contact cast were then allowed to enter the Achilles tendon lengthening group." Judgement Comment: Personnel not blinded. No sham surgery |
| Blinding of outcome assessment (detection bias) | Unclear risk | Judgement Comment: Not blinded outcome assessors however, only objectively assessed outcomes. |
| Incomplete outcome data (attrition bias) | Unclear risk | Judgement Comment: Low attrition however, per protocol analysis (No ITT or description of drop outs) |
| Selective reporting (reporting bias) | Unclear risk | Judgement Comment: No protocol available. Only reporting self-reported data from participants with follow-up data from all time points in separate publication. Thorough reporting of relevant outcomes. |
| Other bias | Low risk | Quote: "8233, St. Louis, MO 63110 In support of their research or preparation of this manuscript, one or more of the authors received grants or outside funding from the National Center for Medical Rehabilitation Research and the National Institutes of Health RO1 HD 36802. None of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated." Judgement Comment: No reason to suspect other sources of bias |

Mueller 2004

| | |
|---------------------|---|
| Methods | <p>Study design: Randomized controlled trial</p> <p>Study grouping: Parallel group</p> |
| Participants | <p>Baseline Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Female, N (%): 3 (21.43%) ● Age, mean (SD): 54.8 (9.5) ● BMI, mean (SD): 33.6 (6) |

| | |
|-----------------------------|--|
| | <ul style="list-style-type: none"> ● <i>Type 2 diabetes, N (%)</i>: 11 (78.57%) ● <i>Duration of diabetes (years)</i>: 19.9 (10.2) ● <i>HbA1c, %</i>: 8.7 (1.8) ● <i>Peripheral neuropathy, N (%)</i>: 14 (100%) <p>Kontrol 1</p> <ul style="list-style-type: none"> ● <i>Female, N (%)</i>: 4 (28.57%) ● <i>Age, mean (SD)</i>: 54.3 (9.9) ● <i>BMI, mean (SD)</i>: 31.8 (6.8) ● <i>Type 2 diabetes, N (%)</i>: 9 (64.29%) ● <i>Duration of diabetes (years)</i>: 17.9 (13.9) ● <i>HbA1c, %</i>: 8.9 (2) ● <i>Peripheral neuropathy, N (%)</i>: 14 (100%) <p>Included criteria: Inclusion criteria were a diagnosis of diabetes, inability to sense a 5.07 (10-g) Semmes-Weinstein monofilament on at least one location on the plantar surface of the foot (indicating loss of protective sensation), recurrent (i.e., two or more episodes) Wagner grade II ulcer (3) on the plantar forefoot or toes, and 5° of passive dorsiflexion range of motion at the talocrural joint as measured using a goniometer with the knee extended.</p> <p>Excluded criteria: Patients were excluded from participation in the study if they were nonambulatory, had a history of rear foot Charcot fractures, had impaired circulation indicated by an ankle-arm index ≤ 0.45, or reported a history of significant health problems that rendered them medically unfit for surgery or post-surgical rehabilitation</p> |
| <p>Interventions</p> | <p>Intervention Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● <i>Description:</i> After wound debridement, subjects assigned to the ATL group underwent a percutaneous ATL procedure before application of a TCC using a modified Hoketripel hemisection technique (8). The first hemisection was on the medial side of the tendon above its insertion into the calcaneus. The second hemisection was also on the medial side of the tendon but below the musculotendinous junction. The final hemisection was on the lateral side of the tendon midway between the two medial cuts (8). A slow controlled force was applied to the forefoot to rotate the ankle joint into 10° of dorsiflexion range of motion (8). A TCC was applied as described above, and patients were progressed from partial to full weight bearing in the cast 1 week after surgery. A padded pressure-relief walking boot (DH Pressure Relief Walker; Royce Medical, Camarillo, CA) was prescribed for 1–4 additional weeks after cast removal, until subjects regained sufficient stability to walk with extra-depth shoes and custom-molded inserts ● <i>Duration:</i> 8 months ● <i>Dose:</i> ATL surgery, TCC change every 2-3 week <p>Kontrol 1</p> <ul style="list-style-type: none"> ● <i>Description:</i> TCC was performed as described previously (6), with the exception that the distal end of the toe box was left open and a standard rocker cast shoe was used. Casts were removed for wound assessment and reapplied after the first week of casting and then every 2–3 weeks until complete epithelialization without drainage was observed. All subjects were instructed to limit their weight-bearing activity during treatment with TCC, and subjects were provided with extra-depth shoes and custom-molded inserts after cast removal according to published recommendations (7). Additionally, a physical therapist instructed all subjects in a home exercise program to perform active ankle plantarflexion, dorsiflexion, inversion, and eversion exercises 3–5 days per week (three sets of 10 repetitions), using appropriate Theraband (Hygenic Corporation, Ipoh, Malaysia) to provide resistance. No supervised therapy was provided beyond this instruction ● <i>Duration:</i> 8 months ● <i>Dose:</i> TCC change every 2-3 week |
| <p>Outcomes</p> | <p><i>Underekstremitets amputationer, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: AdverseEvent ● Reporting: Fully reported ● Unit of measure: Events ● Direction: Lower is better ● Data value: Change from baseline <p><i>Recidiv af sår, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome ● Reporting: Fully reported ● Unit of measure: Events ● Direction: Lower is better ● Data value: Change from baseline <p><i>Mobiliseringsgrad, efter endt behandling</i></p> <ul style="list-style-type: none"> ● Outcome type: ContinuousOutcome ● Reporting: Fully reported ● Direction: Higher is better ● Data value: Endpoint <p><i>Sårhelning (total sårlukning), længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Higher is better ● Data value: Change from baseline <p><i>Sårareal, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: ContinuousOutcome ● Reporting: Not reported ● Data value: Endpoint <p><i>Infektion (positiv dyrkning, eller klinisk (rødme, pus, lugt, hævelse, smerte)), i interventionsperioden</i></p> <ul style="list-style-type: none"> ● Outcome type: AdverseEvent ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Change from baseline <p><i>Bivirkninger (DVT, lungeemboli, komplikationer i relation til operationssår), længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: AdverseEvent ● Reporting: Fully reported |

| | |
|-----------------------|--|
| | <ul style="list-style-type: none"> ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Change from baseline <p><i>Transfersår, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Change from baseline |
| Identification | <p>Sponsorship source: Funding was provided by the National Center for Medical Rehabilitation Research, the National Institutes of Health Grant RO1-HD-36802.</p> <p>Country: USA</p> <p>Setting: Prevention and Control Research Core of the Washington University Diabetes Research Training Center,</p> <p>Authors name: Michael J Mueller</p> <p>Institution: Applied Biomechanics Laboratory, Program in Physical Therapy, Washington University School of Medicine, St. Louis, Missouri</p> <p>Email: muellerm@wustl.edu</p> <p>Address: P.O. Box 8502, 4444 Forest Park Blvd., St. Louis, MO 63108</p> |
| Notes | |

Risk of bias table

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|---|
| Random sequence generation (selection bias) | Low risk | Quote: "The groups were not significantly different with regard to age, ethnicity, BMI, duration of diabetes, HbA1c, sex composition, or the proportion of subjects with type 1 and type 2 diabetes (Table 1)." Quote: "Subjects were randomly assigned to treatment with an ATL procedure followed by TCC (ATL group; n 31) or treatment with TCC alone (TCC group; n 33)." Judgement Comment: From other publication: "Subjects were randomized into the Achilles tendon lengthening group or the total-contact cast group with use of a prearranged schedule generated by a computer program." No baseline differences |
| Allocation concealment (selection bias) | Unclear risk | Judgement Comment: No information about allocation concealment |
| Blinding of participants and personnel (performance bias) | High risk | Judgement Comment: No information about blinding, likely participants and personnel are unblinded |
| Blinding of outcome assessment (detection bias) | High risk | Judgement Comment: No blinding of participants, self-reported outcomes. |
| Incomplete outcome data (attrition bias) | Unclear risk | Quote: "n 14; TCC, n 14). The number of subjects reported in the analyses varies (see Tables 2 and 3) because not all data were available on all 28 subjects." Quote: "A smaller subset of subjects agreed to additional testing as described in this study. Therefore, the analyses described in this study include only those subjects who completed testing on all three test occasions (ATL, n 14; TCC, n 14)." Judgement Comment: of 64 participants, only 28 completed SR measures (all time points) unclear attrition. PP analysis. |
| Selective reporting (reporting bias) | High risk | Judgement Comment: No protocol available. Only reporting data from participants with follow-up data from all time points. |
| Other bias | Low risk | Judgement Comment: No reasons to suspect other sources of bias |

Piaggi 1998

| | |
|---------------------|--|
| Methods | <p>Study design: Randomized controlled trial</p> <p>Study grouping: Parallel group</p> |
| Participants | <p>Baseline Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Age, mean (SD): 65.53 (9.87) ● BMI, mean (SD): 28.12 (13.04) ● Type 2 diabetes, N (%): 19 ● Duration of diabetes (years): 16.84 (10.62) ● HbA1c, %: 8.9 (2.2) ● Peripheral neuropathy, N (%): 21 ● Wound diameter (cm), mean (SD): 4.32 (1.95) <p>Kontrol 1</p> <ul style="list-style-type: none"> ● Age, mean (SD): 63.24 (13.46) ● BMI, mean (SD): 27.71 (9.43) ● Type 2 diabetes, N (%): 17 ● Duration of diabetes (years): 18.20 (8.41) ● HbA1c, %: 9.5 (3.8) ● Peripheral neuropathy, N (%): 20 ● Wound diameter (cm), mean (SD): 4.25 (2.35) <p>Included criteria: Inclusion criteria were: diabetes mellitus (DM), either Type 1 or Type 2, of at least 5 years' duration; presence of one or more painless foot ulcers with clinical characteristics of neuropathy (symptomatic peripheral neuropathy assessed with the Michigan Neuropathy Screening Instrument (MNSI), absence of ankle reflexes, and abnormal vibration perception threshold (VPT.25 V) at malleolus and first toe, according to the methodology described by Younget al.8,9)</p> <p>Excluded criteria: Exclusion criteria were: presence of symptomatic claudication or absence of foot pulses, recent keto-acidosis, renal failure as suggested by creatinine higher than 177mmol l-1, presence of infection as indicated by perilesional oedema and erythema, or presence of pus, systemic symptoms like fever or leukocytosis. In cases of doubt, a wound swab was sent for bacteriological assessment and no suspicious case was enrolled. Patients with congenital foot deformities or diabetic neuroarthropathy, body mass index (BMI).30 kg m-2, clinical history of stroke, cardiac failure, cancer, HIV positivity or history of mental illness were also excluded. To exclude the possibility of subclinical macroangiopathy, a Doppler study was performed in any case of reduced peripheral pulses. An ankle-brachial pressure index (ABPI) less than 0.9 excluded patients from the study. Osteomyelitis was suspected in any case in which the bone or the</p> |

| | |
|-----------------------------|--|
| | <p>joint could be probed through the ulcer. In such cases an X-ray of the foot was examined for signs of osteomyelitis; doubtful cases were excluded</p> |
| <p>Interventions</p> | <p>Intervention Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Description: Group B patients were scheduled for outpatient surgery, after pre-operative evaluation including basal ECG, chest x-ray, blood cell count, plasma chemistry, and virological screening. On the day of surgery, patients had their capillary glucose monitored and controlled with intra-venous infusion of 5 % glucose solution with insulin throughout the operation, in order to maintain plasma glucose between 5.5 and 11.1 mmol l⁻¹. Surgical operations were all carried out with local or regional anaesthesia, patients were observed for 3–4 hours after the intervention and then discharged home. 13 Surgery consisted of the removal of the ulcer through conic ulcerectomy, which removes both the walls and the bottom of the lesion; moreover, in the presence of visible bone segments under the ulcers, or in cases where bone segments might interfere with the closure of the margins of wound, their debridement or removal was performed with scalpels or a rong. To verify the possible presence of osteomyelitis, any resected bone fragments were cultured for microbial or fungal infection. The surgical wound was closed with single stitches and a drain, which was removed after 48 h. The closed wound was covered with sterile gauze and the limb was positioned in slight anti-orthostatic position for 48 h. Then the wounds were treated with antiseptic solution (povidone iodine 50 % + saline 50 %) twice a week. Stitches were removed after 3 weeks. Patients were allowed to walk with crutches and fitted shoes (Podiabetes[®]; Buratto, Treviso, Italy) for the first week, and 4–6 weeks after the operation they were allowed to walk with orthosis and moulded shoes only ● Duration: 6 months ● Dose: change of bandage twice a week, surgery only one time <p>Kontrol 1</p> <ul style="list-style-type: none"> ● Description: Both treatments were performed on an outpatient basis, in the foot clinic of our metabolic department by trained physicians and personnel. Ulcers in group A patients, after initial debridement of lesions and elimination of surrounding hyperkeratosis, were dressed with saline-moistened sterile gauze and patients were advised to change the dressing every 24 h, helped by a specifically trained relative if necessary. They were given special shoes (Podiabetes[®]; Buratto, Treviso, Italy) with a custom-made orthosis to relieve weight from the lesions, and were asked to stand on their feet as little as possible, helping themselves with crutches. 12 They were seen twice a week as outpatients for inspection and control of orthosis. On these occasions lesions were irrigated with an antiseptic solution (povidone iodine 50 % + saline 50 %) and then covered again with saline-moistened gauze. No other medications were used. After healing, patients were provided with a definitive orthosis and moulded shoes. The whole treatment course of group A patients from initial debridement to follow-up visits was performed by physicians and nurses unaware of the participation of patients in the study, and did not differ from the standard protocol of treatment of non-complicated neuropathic ulcerations in our foot clinic ● Duration: 6 months ● Dose: change of bandage every day |
| <p>Outcomes</p> | <p><i>Helbredsrelateret livskvalitet, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Reporting: Fully reported ● Scale: Global satisfaction ● Range: 0-10 ● Unit of measure: Point ● Direction: Higher is better <p><i>Underekstremitets amputationer, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Adverse Event ● Reporting: Fully reported ● Unit of measure: Events ● Direction: Lower is better ● Data value: Change from baseline <p><i>Recidiv af sår, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Reporting: Fully reported ● Unit of measure: Events ● Direction: Lower is better ● Data value: Change from baseline <p><i>Mobiliseringsgrad, efter endt behandling</i></p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Reporting: Fully reported ● Direction: Higher is better ● Data value: Endpoint <p><i>Sårhelning (total sårlukning), længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Higher is better ● Data value: Change from baseline <p><i>Sårareal, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Reporting: Not reported ● Data value: Endpoint <p><i>Infektion (positiv dyrkning, eller klinisk (rødme, pus, lugt, hævelse, smerte)), i interventionsperioden</i></p> <ul style="list-style-type: none"> ● Outcome type: Adverse Event ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Change from baseline <p><i>Bivirkninger (DVT, lungeemboli, komplikationer i relation til operationssår), længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: Adverse Event ● Reporting: Fully reported ● Unit of measure: n/N |

| | |
|-----------------------|---|
| | <ul style="list-style-type: none"> ● Direction: Lower is better ● Data value: Change from baseline <p><i>Transfersår, længste follow-up (op til 1 år)</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome ● Reporting: Fully reported ● Unit of measure: n/N ● Direction: Lower is better ● Data value: Change from baseline |
| Identification | <p>Sponsorship source: no sponsors</p> <p>Country: italy</p> <p>Setting: To test the efficacy of surgical treatment of non-infected neuropathic foot ulcers compared to conventional non-surgical management, a group of diabetic outpatients attending our diabetic foot clinic were studied. Group A received conservative treatment, consisting of relief of weight-bearing, regular dressings; group B underwent surgical excision, eventual debridement or removal of bone segments underlying the lesion and surgical closure</p> <p>Authors name: Alberto Piaggese</p> <p>Institution: Cattedra di Malattie del Metabolismo, Istituto di Clinica Medica II, Università di Pisa, Pisa, Italy</p> <p>Email: no email</p> <p>Address: Unita Operativa Malattie del Ricambio, Azienda Ospedaliera Pisana, Via Paradisa 2, 56100 Pisa, Italy</p> |
| Notes | |

Risk of bias table

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence generation (selection bias) | Low risk | Quote: "After having obtained their informed consent, patients were randomized into two groups according to a table of randomization." Judgement Comment: Unclear how a RANDOM randomization was performed however, no apparent baseline differences between groups (ANOVA analysis not shown) |
| Allocation concealment (selection bias) | Unclear risk | Judgement Comment: No information about who performed the sequence generation and if the allocation was concealed. |
| Blinding of participants and personnel (performance bias) | Unclear risk | Judgement Comment: Efforts made to blind personnel. No efforts to blind described participants, No sham surgery. |
| Blinding of outcome assessment (detection bias) | Unclear risk | Judgement Comment: No information about blinding however, primarily objectively assessed outcomes |
| Incomplete outcome data (attrition bias) | Low risk | Judgement Comment: 20/21 randomised. No info about drop outs or missing data. |
| Selective reporting (reporting bias) | Low risk | Judgement Comment: No protocol registered however, anticipated outcomes thoroughly reported |
| Other bias | Low risk | Judgement Comment: No reasons to suspect other sources of bias |

Footnotes

Characteristics of excluded studies

Resch 2004

| | |
|----------------------|--------------------|
| Reason for exclusion | Wrong study design |
|----------------------|--------------------|

Richter 2012

| | |
|----------------------|--------------------|
| Reason for exclusion | Wrong intervention |
|----------------------|--------------------|

Footnotes

Characteristics of ongoing studies

Finestone 2018

| | |
|---------------------|---|
| Study name | Surgical offloading procedures for diabetic foot ulcers compared to best non-surgical treatment: a study protocol for a randomized controlled trial |
| Methods | RCT |
| Participants | Diabetic foot ulcers |
| Interventions | Surgical offloading procedures vs best non-surgical treatment |
| Outcomes | Outcome criteria will be time to healing of the primary ulcer (complete epithelization), time to healing of surgical wound, recurrence of ulcer, time to recurrence and complications |
| Starting date | 2018 |
| Contact information | asff@inter.net.it |
| Notes | Protocol registration: https://my.health.gov.il/CliniTrials/Pages/MOH_2017-08-10_000719.aspx |

Footnotes

References to studies

Included studies

Allam 2006

Allam, A. M.. Impact of Achilles tendon lengthening (ATL) on the diabetic plantar forefoot ulceration.. 2006;30(Journal Article):43-8. [DOI:]

Mueller 2003

Mueller, M. J.; Sinacore, D. R.; Hastings, M. K.; Strube, M. J.; Johnson, J. E.. Effect of Achilles tendon lengthening on neuropathic plantar ulcers. A randomized clinical trial. The Journal of bone and joint surgery.American volume 2003;85(8):1436-1445. [DOI:]

Mueller 2004

Mueller M.J.; Sinacore D.R.; Hastings M.K.; Lott D.J.; Strube M.J.; Johnson J.E.. Impact of Achilles tendon lengthening on functional limitations and perceived disability in people with a neuropathic plantar ulcer. Diabetes care 2004;27(7):1559-1564. [DOI: <http://dx.doi.org/10.2337/diacare.27.7.1559>]

Piaggese 1998

Piaggese A; Schipani E; Campi F; Romanelli M; Baccetti F; Arvia C; Navalesi R. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial.. Diabet Med 1998;15(5):412-7. [DOI: [10.1002/\(SICI\)1096-9136\(199805\)15:5<412::AID-DIA584>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1096-9136(199805)15:5<412::AID-DIA584>3.0.CO;2-1)]

Excluded studies

Resch 2004

Resch, Sylvia. Corrective surgery in diabetic foot deformity. Diabetes/metabolism research and reviews 2004;20 Suppl 1(Journal Article):S34-6. [DOI:]

Richter 2012

Richter, Martinus; Zech, Stefan. Four-stage regimen for operative treatment of diabetic foot ulcer with deformity - a results of 300 patients. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons 2012;18(4):247-54. [DOI: <https://dx.doi.org/10.1016/j.fas.2012.03.001>]

Ongoing studies

Finestone 2018

Finestone, Aharon S.; Tamir, Eran; Ron, Guy; Wisner, Itay; Agar, Gabriel. Surgical offloading procedures for diabetic foot ulcers compared to best non-surgical treatment: a study protocol for a randomized controlled trial. Journal of foot and ankle research 2018;11(Journal Article):6. [DOI: <https://dx.doi.org/10.1186/s13047-018-0248-3>]


Data and analyses

1 Aflastende kirurgi vs standard sårbehandling

| Outcome or Subgroup | Studies | Participants | Statistical Method | Effect Estimate |
|--|---------|--------------|--------------------------------------|---------------------|
| 1.1 Recidiv af sår, længste follow-up (op til 1 år) | 3 | 123 | Risk Ratio (IV, Random, 95% CI) | 0.30 [0.15, 0.58] |
| 1.2 Underekstremitets amputationer, længste follow-up (op til 1 år) | 2 | 105 | Risk Ratio (IV, Random, 95% CI) | 0.34 [0.04, 3.12] |
| 1.3 Sårheling (total sårlukning), længste follow-up (op til 1 år) | 3 | 138 | Risk Ratio (IV, Random, 95% CI) | 1.08 [0.99, 1.17] |
| 1.4 Transfersår, længste follow-up (op til 1 år), risk ratio | 2 | 93 | Risk Ratio (IV, Random, 95% CI) | 6.75 [0.86, 53.13] |
| 1.5 Transfersår, længste follow-up (op til 1 år), risk difference | 2 | 93 | Risk Difference (IV, Random, 95% CI) | 0.13 [0.02, 0.24] |
| 1.6 Infektion, i interventionsperioden | 2 | 110 | Risk Ratio (IV, Random, 95% CI) | 0.79 [0.10, 6.03] |
| 1.7 Bivirkninger, længste follow-up (op til 1 år), risk ratio | 3 | 134 | Risk Ratio (IV, Random, 95% CI) | 1.28 [0.36, 4.57] |
| 1.8 Bivirkninger, længste follow-up (op til 1 år), risk difference | 3 | 134 | Risk Ratio (IV, Random, 95% CI) | 1.28 [0.36, 4.57] |
| 1.9 Selvrapporeret funktion, efter endt behandling | 1 | 25 | Mean Difference (IV, Fixed, 95% CI) | 3.70 [-2.46, 9.86] |
| 1.10 Helbredsrelateret livskvalitet, længste follow-up (op til 1 år) | 1 | 25 | Mean Difference (IV, Random, 95% CI) | 3.80 [-4.41, 12.01] |
| 1.11 Sårareal, længste follow-up (op til 1 år) | 0 | 0 | Mean Difference (IV, Fixed, 95% CI) | Not estimable |
| 1.12 Mobiliseringsgrad, efter endt behandling | 0 | 0 | Mean Difference (IV, Fixed, 95% CI) | Not estimable |

Figures

Figure 1 (Analysis 1.1)




Footnotes

- (1) 8 months follow-up. Achilles tendon lengthening + TCC vs TCC
- (2) 11 months follow-up. Conic ulcerectomy.

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.1 Recidiv af sår, længste follow-up (op til 1 år).

Figure 2 (Analysis 1.2)




Footnotes

- (1) 8 months follow-up. Achilles tendon lengthening + TCC vs TCC
- (2) 11 months follow-up. Conic ulcerectomy.

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.2 Underekstremitets amputationer, længste follow-up (op til 1 år).

Figure 3 (Analysis 1.3)




Footnotes

- (1) 12 months follow-up. Achilles tendon lengthening vs TCC
- (2) 8 months follow-up. Achilles tendon lengthening + TCC vs TCC
- (3) 11 months follow-up. Conic ulcerectomy.

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.3 Sårheling (total sårtilknytning), længste follow-up (op til 1 år).

Figure 4 (Analysis 1.4)




Footnotes

- (1) Heel ulcers. 8 months follow-up. Achilles tendon lengthening + TCC vs TCC

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.4 Transfersår, længste follow-up (op til 1 år), risk ratio.

Figure 5 (Analysis 1.5)



Footnotes


(1) Heel ulcers. 8 months follow-up. Achilles tendon lengthening + TCC vs TCC

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.5 Transfersår, længste follow-up (op til 1 år), risk difference.

Figure 6 (Analysis 1.6)



Footnotes


(1) 8 months follow-up. Achilles tendon lengthening + TCC vs TCC
(2) 6 months follow-up. Conic ulcerectomy.

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.6 Infektion, i interventionsperioden.

Figure 7 (Analysis 1.7)



Footnotes


(1) Superficial abrasio, allergy to cast. 8 months follow-up. Achilles tendon lengthening + TCC vs TCC.
(2) Two minor surgical complications, breaking of stiches, drain self removal. 11 months follow-up....

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.7 Bivirkninger, længste follow-up (op til 1 år), risk ratio.

Figure 8 (Analysis 1.8)



Footnotes


(1) Superficial abrasio, allergy to cast. 8 months follow-up. Achilles tendon lengthening + TCC vs TCC.
(2) Two minor surgical complications, breaking of stiches, drain self removal. 11 months follow-up....

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.8 Bivirkninger, længste follow-up (op til 1 år), risk difference.

Figure 9 (Analysis 1.9)



Footnotes


(1) Timepoint: Post ulcer healing. SF-36 Physical functioning (0-100, higher better). Achilles tendon...

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.9 Selvrapporteret funktion, efter endt behandling.

Figure 10 (Analysis 1.10)



Footnotes


(1) 8 months follow-up. SF-36, General Health (0-100, higher better). Achilles tendon lengthening + TCC vs...

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Forest plot of comparison: 1 Aflastende kirurgi vs standard sårbehandling, outcome: 1.10 Helbredsrelateret livskvalitet, længste follow-up (op til 1 år).

Figure 11



Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Figure 12



Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.